Antibodies News and Research

RSS

Researchers, policymakers to gather at AIDS Vaccine 2012 conference in Boston

"With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers of AIDS Vaccine 2012 say," the Center for Global Health Policy's "Science Speaks" blog reports.

7 Sep 2012

Outbreak of autoimmune disease with AIDS-like symptoms in Southeast Asia

There has been an outbreak of an adult-onset immunodeficiency syndrome in Southeast Asia. The autoimmune disease causes AIDS-like symptoms but is not associated with HIV and is not contagious.

7 Sep 2012

Therapeutic targets for pemphigus vulgaris discovered

Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.

7 Sep 2012

Long-term prognosis excellent for patients with IgA nephropathy

For patients with a common kidney disease who have normal kidney function and only minor urinary abnormalities at the time of diagnosis, the long-term prognosis is excellent and no special treatments are needed, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

7 Sep 2012

Biopsies may misdiagnose eosinophilic esophagitis

University of Utah engineers mapped white blood cells called eonsinophils and showed an existing diagnostic method may overlook an elusive digestive disorder that causes swelling in the esophagus and painful swallowing.

7 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

GE Healthcare introduces KUBio factory

GE Healthcare, the healthcare business of GE, today introduced KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

4 Sep 2012

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.

4 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Researchers define new treatment for potentially fatal lung disease in patients with CVID

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).

1 Sep 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Scientists open new front against cause of sleeping sickness

Scientists of the Antwerp Institute of Tropical Medicine (ITG) opened a new front against the cause of sleeping sickness. This parasite is transmitted between humans by tsetse flies. The researchers learned a bacterium living in those flies how to produce antibodies against the parasite. Application in the field is still a long way of, but the technique shows quite some promise.

31 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Cholera toxin binds differently to intestinal cells than previously thought

The likelihood of becoming seriously ill from cholera depends on your blood group. It is possible to find a new remedy for the feared illness by studying the molecular structure in the toxin in the cholera bacteria.

28 Aug 2012

HIV-like immunodeficiency observed in Asia

Researchers have discovered an adult-onset immunodeficiency syndrome with symptoms similar to those of advanced HIV in Thailand and Taiwan.

24 Aug 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012